Raymond James Financial Services Advisors Inc. Has $695,000 Stock Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Raymond James Financial Services Advisors Inc. trimmed its holdings in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 91.4% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,940 shares of the medical research company's stock after selling 31,134 shares during the quarter. Raymond James Financial Services Advisors Inc.'s holdings in Charles River Laboratories International were worth $695,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently modified their holdings of the business. AMG National Trust Bank bought a new stake in Charles River Laboratories International during the 3rd quarter valued at about $1,119,000. CGN Advisors LLC purchased a new stake in shares of Charles River Laboratories International during the 4th quarter valued at about $1,663,000. Trexquant Investment LP purchased a new stake in shares of Charles River Laboratories International during the 3rd quarter valued at about $4,104,000. AQR Capital Management LLC boosted its holdings in shares of Charles River Laboratories International by 29.6% during the 3rd quarter. AQR Capital Management LLC now owns 84,616 shares of the medical research company's stock valued at $16,583,000 after acquiring an additional 19,347 shares during the last quarter. Finally, Gateway Investment Advisers LLC boosted its holdings in shares of Charles River Laboratories International by 17.8% during the 4th quarter. Gateway Investment Advisers LLC now owns 1,480 shares of the medical research company's stock valued at $350,000 after acquiring an additional 224 shares during the last quarter. 98.91% of the stock is currently owned by institutional investors.

Charles River Laboratories International Price Performance

Charles River Laboratories International stock traded down $2.54 during mid-day trading on Thursday, reaching $227.55. 707,817 shares of the company's stock traded hands, compared to its average volume of 550,575. The company has a market cap of $11.72 billion, a price-to-earnings ratio of 24.71, a PEG ratio of 1.82 and a beta of 1.40. The stock has a 50 day moving average of $253.64 and a two-hundred day moving average of $220.96. The company has a quick ratio of 1.16, a current ratio of 1.52 and a debt-to-equity ratio of 0.73. Charles River Laboratories International, Inc. has a 12-month low of $161.65 and a 12-month high of $275.00.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its quarterly earnings results on Wednesday, February 14th. The medical research company reported $2.46 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.39 by $0.07. The company had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $991.25 million. Charles River Laboratories International had a net margin of 11.49% and a return on equity of 16.53%. Charles River Laboratories International's revenue was down 7.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.98 earnings per share. Equities analysts forecast that Charles River Laboratories International, Inc. will post 11.01 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on CRL. Evercore ISI raised their price target on shares of Charles River Laboratories International from $260.00 to $265.00 and gave the company an "outperform" rating in a report on Thursday, February 15th. UBS Group raised their price target on shares of Charles River Laboratories International from $270.00 to $290.00 and gave the company a "buy" rating in a report on Thursday, February 15th. Citigroup raised their price objective on shares of Charles River Laboratories International from $215.00 to $250.00 and gave the stock a "neutral" rating in a report on Thursday, February 15th. TheStreet raised shares of Charles River Laboratories International from a "c+" rating to a "b-" rating in a report on Friday, March 1st. Finally, Argus raised their price objective on shares of Charles River Laboratories International from $240.00 to $290.00 and gave the stock a "buy" rating in a report on Monday, March 18th. Five research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $253.23.

Insider Activity

In other news, EVP Shannon M. Parisotto sold 5,882 shares of the stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $241.20, for a total value of $1,418,738.40. Following the sale, the executive vice president now owns 2,596 shares of the company's stock, valued at $626,155.20. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, EVP Shannon M. Parisotto sold 5,882 shares of the stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $241.20, for a total value of $1,418,738.40. Following the sale, the executive vice president now owns 2,596 shares of the company's stock, valued at $626,155.20. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, VP William D. Barbo sold 4,050 shares of the stock in a transaction on Thursday, February 22nd. The shares were sold at an average price of $248.50, for a total transaction of $1,006,425.00. Following the completion of the sale, the vice president now directly owns 22,879 shares in the company, valued at approximately $5,685,431.50. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 14,932 shares of company stock valued at $3,693,663. 1.30% of the stock is currently owned by company insiders.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).